

RESEARCH

Open Access



Not only lymphadenopathy: case of chest lymphangitis assessed with MRI after COVID 19 vaccine

Vincenza Granata^{1*}, Roberta Fusco², Paolo Vallone¹, Sergio Venanzio Setola¹, Carmine Picone¹, Francesca Grassi^{3,4}, Renato Patrone⁵, Andrea Belli⁵, Francesco Izzo⁵ and Antonella Petrillo¹

Abstract

Background: To date, no paper reports cases of lymphangitis after COVID 19 vaccination. We present a case of lymphangitis after vaccination from COVID 19, in a patient with colorectal liver metastases.

Methods: We described the case of a 56-year-old woman with history of a surgical resection of colorectal cancer and liver metastases, without any kind of drug therapy for about a month. In addition, a recent administration (2 days ago) of Spikevax (mRNA-1273, Moderna vaccine), as a booster dose, on the right arm was reported.

Results: The magnetic resonance (MR) examination showed the effects of the previous surgical resection and five new hepatic metastases, located in the VIII, VI, V, IV and II hepatic segments. As an accessory finding the presence of lymphadenopathy in the axillary area and lymphangitis of the right breast and chest were identified. The computed tomography scan performed a week earlier, and re-evaluated in light of the MR data, did not identify the presence of lymphadenopathy in the axillary area and lymphangitis signs.

Conclusions: Lymphangitis could occur after COVID 19 vaccine and it is important to know this data to avoid alarmism in patients and clinicians and economic waste linked to the execution of various radiological investigations for the search for a tumour that probably does not exist.

Trial registration: Not applicable.

Keywords: Chest lymphangitis, COVID 19, Vaccination, MRI

Introduction

A new coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) is the pathogen responsible for the SARS-CoV-2 disease (COVID-19), which has spread throughout the world since December 2019 [1–8]. COVID-19 was defined as a pandemic by the World Health Organization on 11 March 2020. The clinical spectrum of COVID-19 range from flu-like symptoms to

respiratory failure, the management of which demands advanced respiratory assistance and artificial ventilation [9–21]. Currently, a valuable therapy has not yet been improved so that mechanical respiratory support is the only treatment in critically ill patients. In this scenario, it has been critical to develop a vaccine as soon as possible, to prevent SARS-CoV-2 infection in order to protect persons who are at high risk for complications. Globally, at the time of writing, 5 January 2022, there have been 290,959,019 confirmed cases of COVID-19, including 5,446,753 deaths, reported to WHO. As of 3 January 2022, a total of 8,693,832,171 vaccine doses have been administered. In Italy, from 3 January 2020 to 6:18 pm

*Correspondence: v.granata@istitutotumori.na.it

¹ Division of Radiology, "Istituto Nazionale Tumori IRCCS Fondazione Pascale – IRCCS di Napoli", Naples, Italy

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

CET, 4 January 2022, there have been 6,396,110 confirmed cases of COVID-19 with 137,786 deaths, reported to WHO. As of 19 December 2021, a total of 104,968,360 vaccine doses have been administered [22].

The Italian authorities have used the following vaccination strategy: two vaccine doses, with a booster dose 5–6 months after the end of the vaccination cycle, in patients who have not been infected. A strategy for monitoring vaccine adverse events is based on the collaboration of local and national health structures, assisted by Italian Medicines Agency (AIFA) [23–25].

Since the beginning of their administration, various reactions and adverse effects of the COVID-19 vaccines have been reported and shared world-wide [4, 24–38]. While vaccine-related lymphadenopathy (LAP) with other vaccines is rare, reports of regional LAP in COVID-19 vaccine recipients are gradually increasing along with the rollout of mass COVID-19 vaccination across the world [24]. LAP can be alarming especially in patients with a history of cancer.

To date, no paper reports cases of lymphangitis after COVID 19 vaccination. We present a case of lymphangitis after vaccination from Covid-19, in a patient with colorectal liver metastases.

Methods

The study was managed according to the Declaration of Helsinki guidelines. Approval by the Institutional Review Board was not needed considering the nature of the study: the description of a single case report. Informed consent was obtained by the patient. On 5 January 2022, a 56-year-old woman patient arrived at Division of Radiology, “Istituto Nazionale Tumori IRCCS Fondazione Pascale – IRCCS di Napoli”, Naples, Italy, to be submitted to liver MRI in the pre surgical setting. In anamnesis, colorectal cancer surgical resection and liver metastases resection were reported, without any kind

of drug therapy for about a month. In addition, a recent administration (2 days ago) of Spikevax (mRNA-1273, Moderna vaccine), as a booster dose on the right arm was reported.

MR examination was performed in a pre-surgical setting, in order to identify all new liver metastases with a 1.5 T MR scanner, Magnetom Symphony (Siemens, Erlangen, Germany) equipped with an 8-element body and phased array coils. The MRI study included pre- and post-contrast images obtained before and post intravenous (IV) contrast agent (CA) injection. MRI sequences were coronal Trufisp T2-weighted free breathing; axial Half-Fourier Acquisition Single-Shot Turbo Spin-Echo (HASTE) T2-weighted, with controlled respiration, without and with fat-suppressed (FS) gradient-echo pulse; coronal HASTE T2-weighted, without FS; axial flash in-out phase T1-weighted, with controlled respiration; Volumetric Interpolated Breath-hold Examination (VIBE) T1-weighted SPAIR with controlled respiration before and after the administration of a liver-specific CA, the Gd-EOB-BPTA (Primovist, Bayer Schering Pharma, Berlin, Germany). The patient received 0.1 mL/kg of Gd-EOB-BPTA by means of a power injector (Spectris Solaris® EP MR, MEDRAD Inc., Indianola, IA, USA) at an infusion rate of 2 mL/s.

Results

The liver MR study showed previous surgical resection effects and five new hepatic lesions, located in the VIII, VI, V, IV and II hepatic segments. As accessory findings, the presence of lymphadenopathy in the axillary area and lymphangitis of the right breast and chest were identified (Figs. 1, 2). The computed tomography (CT) scan performed a week earlier, and re-evaluated in light of the MR data, did not identify the presence of lymphadenopathy in the axillary area and lymphangitis (Fig. 3).




Fig. 1 Magnetic resonance study: T2-W fat suppressed sequences in axial plane. White arrows show breast and chest lymphangitis (A–C). Red arrows show lymphadenopathy (A–C)




Fig. 2 Magnetic resonance study: diffusion weighted imaging (DWI) sequences in axial plane (**A**: b50 s/mm²; **B**: b500 s/mm² and **C**: b800 s/mm²). White arrows show breast and chest lymphangitis (**A–C**). Red arrows show lymphadenopathy (**A–C**)




Fig. 3 Computed tomography study do not identify the presence of lymphadenopathy in the axillary area and lymphangitis (**A, B**)

Therefore, in the same day, the patient was evaluated with an ultrasound (US) examination, performed by dedicated radiologist, using RS85 Samsung System (Samsung Healthcare GmbH, Schwalbach, Germany) in combination with a linear 5 to 12-MHz array transducer. Four nodes were assessed; the largest diameter was 18 mm with a range from 8 to 18 mm (median value = 12 mm). In the same patient we found different US findings: eccentric cortical thickening with wide echogenic hilum and oval shape, asymmetric eccentric cortical thickening with wide echogenic hilum and oval shape, hypoechoic lymph node round shape without hilum. No anomaly was found on the Doppler study. The US showed skin thickening of the right breast without parenchymal lesions.

The analysis of the patient's radiological archive, allowed to re-evaluate the CT scan performed a week earlier, which showed no other neoplasms other than

liver metastases, so as the mammography, performed 2 months earlier, which did not show breast cancer.

Considering the radiological data and the temporal consequentiality with the COVID 19 vaccine, we did diagnosis of lymphangitis due to COVID 19 vaccine.

Discussion

Although the presence of lymphadenopathy at the site of inoculation of the COVID 19 vaccine is well known [39–42], we have presented, to the best of our knowledge, the first case of cutaneous lymphangitis, in the chest and in the breast due to the COVID 19 vaccine. Knowing this clinical data, which can be found accidentally during radiological examinations, is extremely important, especially in cancer patients. In fact, it is known that various tumours can present with lymphangitis [43–45]. Cutaneous lymphangitis is a rare condition accounting for less than 5% of skin metastases. A literature review

identified eight other cases of cutaneous lymphangitis in patients with lung cancer [45], while this condition is present after breast carcinoma in about 23.9% of patients [43], often involving the chest and abdomen and manifesting on average 5 years after surgical removal of the first malignancy. Cutaneous Metastases of breast cancer are usually solitary or multiple nodular pinkish lesions (ranging between 1 and 3 cm). However, several clinical features have been reported in the literature, including telangiectatic carcinoma, erythema-like, erythema annulare centrifugum-like, morphea-like, erysipelas-like, dermatofibroma-like, herpes-zoster-like, and alopecia-like lesions [43].

Skin metastases have the following distribution in women with primary malignancies: breast (69%), large intestine (9%), melanoma (5%), lung (4%), ovary (4%), sarcoma (2%), pancreas (2%), and uterine cervix (2%) [46], and in some cases, it could be the first sign of disease. Therefore, it is our opinion that it is important to spread the knowledge of this new effect of the COVID 19 vaccine for several reasons. Primarily in order not to create alarmism in patients and clinicians and secondly, but no less important for clear economic effects. In fact, a datum seen as an occult sign of neoplasm could determine an economic waste linked to the execution of various radiological investigations, even very expensive, for the search for a tumour that probably does not exist. Radiological examinations that often involve the use of ionizing radiation, with known effects on the health of citizens [47, 48], should be optimized ensuring the lowest reasonably achievable exposure levels (ALARA principle) [49–55].

COVID-19 vaccination-induced lymphadenopathy is increasingly seen on breast imaging; management can be confounded by current or past cancer history. Management of vaccine-related adenopathy detected on breast MRI or other cross-sectional imaging currently varies across radiology practices [56–68]. The management algorithm for adenopathy seen after recent COVID-19 vaccination in a high risk or known breast cancer patient might differ from an average risk patient with adenopathy seen on an otherwise benign-appearing screening mammogram. As the population continues to be vaccinated in larger numbers, adenopathy caused by COVID-19 vaccination will be increasingly seen by breast radiologists and could result in screening call-backs, additional workups, and false positive biopsies [56]. Management of adenopathy in patients with a history of cancer should consider the probability of nodal metastasis, based on original cancer diagnosis (type and location of primary malignancy, expected recurrence patterns) and presence of other suspicious imaging findings or suspicious clinical findings [56]. More recent literature reveals that

some centers consider recent COVID-19 vaccination a known inflammatory cause of unilateral axillary adenopathy and therefore recommend a benign assessment (BI-RADS category 2), if adenopathy is ipsilateral to the site of recent COVID-19 vaccination and not palpable. Management recommendations vary by institution, although recommendations have been recently published that offer practical algorithms for management of adenopathy seen after COVID-19 vaccination [57].

Despite the fact that the preventive efficacy of COVID-19 vaccines is debated in clinical trials, the knowledge about what happens following vaccination in the real world is still modest, especially among the general population. Thus, knowing what to expect after vaccination will help with public education, dispelling myths, and lowering the apprehension about COVID-19 vaccines.

Conclusions

Lymphangitis could occur after COVID 19 vaccine and it is important to know this data to avoid alarmism in patients and clinicians and economic waste linked to the execution of various radiological investigations for the search for a tumour that probably does not exist.

Acknowledgements

The authors are grateful to Alessandra Trocino, librarian at the National Cancer Institute of Naples, Italy. Moreover, for the collaboration, authors are grateful for the research support to Paolo Pariate, Martina Totaro and Andrea Esposito of Radiology Division, "Istituto Nazionale Tumori IRCCS Fondazione Pascale – IRCCS di Napoli", Naples, I-80131, Italy

Authors' contributions

Each author has participated sufficiently to take public responsibility for the content of the manuscript. All authors read and approved the final manuscript.

Funding

No Funding.

Availability of data and materials

Data are available at <https://zenodo.org/record/6111641#.Yh-hfOjMK3A>.

Declarations

Ethics approval and consent to participate

The study was conducted according to the guidelines of the Declaration of Helsinki. Approval by the Institutional Review Board was not needed considering the nature of the study: the findings description of a single case report.

Consent for publication

Informed consent was obtained by the patient.

Competing interests

The authors have no conflicts of interest to be disclosed.

Author details

¹Division of Radiology, "Istituto Nazionale Tumori IRCCS Fondazione Pascale – IRCCS di Napoli", Naples, Italy. ²Medical Oncology Division, Igea SpA, Naples, Italy. ³Italian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, Via della Signora 2, 20122 Milan, Italy. ⁴Division of Radiology,

"Università degli Studi della Campania Luigi Vanvitelli", Naples, Italy. ⁵Division of Hepatobiliary Surgical Oncology, "Istituto Nazionale Tumori IRCCS Fondazione Pascale – IRCCS di Napoli", Naples, Italy.

Received: 12 January 2022 Accepted: 16 February 2022

Published online: 17 March 2022

References

- Stramare R, Carretta G, Capizzi A, Boemo DG, Contessa C, Motta R, De Conti G, Causin F, Giraudo C, Donato D. Radiological management of COVID-19: structure your diagnostic path to guarantee a safe path. *Radiol Med.* 2020;125:691–4.
- Granata V, Fusco R, Izzo F, Venzano Setola S, Coppola M, Grassi R, Reginelli A, Cappabianca S, Grassi R, Petrillo A. COVID-19 infection in cancer patients: the management in a diagnostic unit. *Radiol Oncol.* 2021;55:121–9.
- Gaia C, Maria Chiara C, Silvia L, Chiara A, Maria Luisa C, Giulia B, Silvia P, Lucia C, Alessandra T, Annarita S, et al. Chest CT for early detection and management of coronavirus disease (COVID-19): a report of 314 patients admitted to Emergency Department with suspected pneumonia. *Radiol Med.* 2020;125:931–42.
- Reginelli A, Grassi R, Feragalli B, Belfiore MP, Montanelli A, Patelli G, La Porta M, Urraro F, Fusco R, Granata V, et al. Coronavirus disease 2019 (COVID-19) in Italy: double reading of chest CT examination. *Biology.* 2021;10:89.
- Giovagnoni A. Facing the COVID-19 emergency: we can and we do. *Radiol Med.* 2020;125:337–8.
- Montesi G, Di Biase S, Chierchini S, Pavanato G, Viridis GE, Contato E, Mandoliti G. Radiotherapy during COVID-19 pandemic. How to create a No fly zone: a Northern Italy experience. *Radiol Med.* 2020;125:600–3.
- Ilerardi AM, Wood BJ, Arrichiello A, Bottino N, Bracchi L, Forzenigo L, Andrisani MC, Vespro V, Bonelli C, Amalou A, et al. Preparation of a radiology department in an Italian hospital dedicated to COVID-19 patients. *Radiol Med.* 2020;125:894–901.
- Grassi R, Cappabianca S, Urraro F, Feragalli B, Montanelli A, Patelli G, Granata V, Giacobbe G, Russo GM, Grillo A, et al. Chest CT computerized aided quantification of PNEUMONIA lesions in COVID-19 infection: a comparison among three commercial software. *Int J Environ Res Public Health.* 2020;17:6914.
- Pediconi F, Galati F, Bernardi D, Belli P, Brancato B, Calabrese M, Camera L, Carbonaro LA, Caumo F, Clauser P, et al. Breast imaging and cancer diagnosis during the COVID-19 pandemic: recommendations from the Italian College of Breast Radiologists by SIRM. *Radiol Med.* 2020;10:926–30.
- Koc A, Sezgin OS, Kayipmaz S. Comparing different planimetric methods on volumetric estimations by using cone beam computed tomography. *Radiol Med.* 2020;125:398–405.
- Agostini A, Floridi C, Borgheresi A, Badaloni M, Esposito Pirani P, Terilli F, Ottaviani L, Giovagnoni A. Proposal of a low-dose, long-pitch, dual-source chest CT protocol on third-generation dual-source CT using a tin filter for spectral shaping at 100 kVp for Coronavirus Disease 2019 (COVID-19) patients: a feasibility study. *Radiol Med.* 2020;125:365–73.
- Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression. *Radiol Med.* 2020;125:509–13.
- Neri E, Miele V, Coppola F, Grassi R. Use of CT and artificial intelligence in suspected or COVID-19 positive patients: statement of the Italian Society of Medical and Interventional Radiology. *Radiol Med.* 2020;125:505–8.
- Carotti M, Salaffi F, Sarzi-Puttini P, Agostini A, Borgheresi A, Minorati D, Galli M, Marotto D, Giovagnoni A. Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists. *Radiol Med.* 2020;125:636–46.
- Grassi R, Belfiore MP, Montanelli A, Patelli G, Urraro F, Giacobbe G, Fusco R, Granata V, Petrillo A, Sacco P, et al. COVID-19 pneumonia: computer-aided quantification of healthy lung parenchyma, emphysema, ground glass and consolidation on chest computed tomography (CT). *Radiol Med.* 2021;126:553–60.
- Fichera G, Stramare R, De Conti G, Motta R, Giraudo C. It's not over until it's over: the chameleonic behavior of COVID-19 over a six-day period. *Radiol Med.* 2020;5:514–6.
- Borghesi A, Zigliani A, Masciullo R, Golemi S, Maculotti P, Farina D, Maroldi R. Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients. *Radiol Med.* 2020;125:461–4.
- Cozzi D, Albanesi M, Cavigli E, Moroni C, Bindi A, Luvàra S, Lucarini S, Busoni S, Mazzoni LN, Miele V. Chest X-ray in new Coronavirus disease 2019 (COVID-19) infection: findings and correlation with clinical outcome. *Radiol Med.* 2020;125:730–7.
- Gatti M, Calandri M, Barba M, Biondo A, Geninatti C, Gentile S, Greco M, Morrone V, Piatti C, Santonocito A, et al. Baseline chest X-ray in coronavirus disease 19 (COVID-19) patients: association with clinical and laboratory data. *Radiol Med.* 2020;125:1271–9.
- Giannitto C, Spota FM, Repici A, Vatteroni G, Casiraghi E, Casari E, Ferraroli GM, Fugazza A, Sandri MT, Chiti A, et al. Chest CT in patients with a moderate or high pretest probability of COVID-19 and negative swab. *Radiol Med.* 2020;125:1260–70.
- Fusco R, Grassi R, Granata V, Setola SV, Grassi F, Cozzi D, Pecori B, Izzo F, Petrillo A. Artificial intelligence and COVID-19 using chest CT scan and chest X-ray images: machine learning and deep learning approaches for diagnosis and treatment. *J Pers Med.* 2021;11:993.
- <https://covid19.who.int>.
- <https://www.aifa.gov.it>.
- Granata V, Fusco R, Setola SV, Galdiero R, Picone C, Izzo F, D'Aniello R, Miele V, Grassi R, Grassi R, et al. Lymphadenopathy after BNT162b2 Covid-19 vaccine: preliminary ultrasound findings. *Biology.* 2021;10:214.
- Moderna COVID-19 vaccine (2021). <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine>. Accessed Apr 8 2021.
- Pfizer-BioNTech COVID-19 vaccine (2021). <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine>.
- Janssen COVID-19 vaccine (2021). <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine>.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med.* 2021;384:403–16.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med.* 2020;383:2603–15.
- Local reactions, systemic reactions, adverse events, and serious adverse events: Pfizer-BioNTech COVID-19 vaccine (2021). <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html>. Accessed Aug 4 2021.
- Di Serafino M, Notaro M, Rea G, Iacobellis F, Paoli VD, Acampora C, Ianniello S, Brunese L, Romano L, Vallone G. The lung ultrasound: facts or artifacts? In the era of COVID-19 outbreak. *Radiol Med.* 2020;125:738–53.
- Grassi R, Belfiore MP, Montanelli A, Patelli G, Urraro F, Giacobbe G, Fusco R, Granata V, Petrillo A, Sacco P, et al. COVID-19 pneumonia: computer-aided quantification of healthy lung parenchyma, emphysema, ground glass and consolidation on chest computed tomography (CT). *Radiol Med.* 2021;126(4):553–60.
- Özel M, Aslan A, Araç S. Use of the COVID-19 reporting and data system (CO-RADS) classification and chest computed tomography involvement score (CT-IS) in COVID-19 pneumonia. *Radiol Med.* 2021;126:1–9.
- Ilerardi AM, Gaibazzi N, Tuttolomondo D, Fusco S, La Mura V, Peyvandi F, Aliberti S, Blasi F, Cozzi D, Carrafiello G, et al. Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables. *Radiol Med.* 2021;126:1–7.
- Ippolito D, Giandola T, Maino C, Pecorelli A, Capodaglio C, Ragusi M, Porta M, Gandola D, Masetto A, Drago S, et al. Acute pulmonary embolism in hospitalized patients with SARS-CoV-2-related pneumonia: multicentric experience from Italian endemic area. *Radiol Med.* 2021;126:1–10.
- Moroni C, Cozzi D, Albanesi M, Cavigli E, Bindi A, Luvàra S, Busoni S, Mazzoni LN, Grifoni S, Nazerian P, et al. Chest X-ray in the emergency department during COVID-19 pandemic descending phase in Italy: correlation with patients' outcome. *Radiol Med.* 2021;126:1–8.
- Cereser L, Girometti R, Da Re J, Marchesini F, Como G, Zuiani C. Inter-reader agreement of high-resolution computed tomography findings in patients with COVID-19 pneumonia: a multi-reader study. *Radiol Med.* 2021;126:1–8.
- Granata V, Ianniello S, Fusco R, Urraro F, Pupo D, Magliocchetti S, Albarello F, Campioni P, Cristofaro M, Di Stefano F, Fusco N, Petrone A, Schinà V, Villanacci A, Grassi F, Grassi R, Grassi R. Quantitative analysis of residual

- COVID-19 lung CT features: consistency among two commercial software. *J Pers Med*. 2021;11(11):1103.
39. D'Agostino V, Caranci F, Negro A, Piscitelli V, Tuccillo B, Fasano F, Sirabella G, Marano I, Granata V, Grassi R, Pupo D, Grassi R. A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration. *J Pers Med*. 2021;11(4):285.
40. Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, Mohamud R. Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. *Vaccines (Basel)*. 2021;9(6):556.
41. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. *Eur Rev Med Pharmacol Sci*. 2021;25(3):1663–9.
42. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, Olson SM, Talbot HK, Casey JD, Mohr NM, Zepeski A, McNeal T, Ghamande S, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Gong MN, Mohamed A, Henning DJ, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CL, Busse LW, Ten Lohuis CC, Duggal A, Wilson JG, Gordon AJ, Qadir N, Chang SY, Mallow C, Rivas C, Babcock HM, Kwon JH, Exline MC, Halasa N, Chappell JD, Luring AS, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart KW, Zhu Y, Mills L, Lester SN, Stumpf MM, Naioti EA, Kobayashi M, Verani JR, Thornburg NJ, Patel MM, IVY Network. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(38):1337–43.
43. Paolino G, Panetta C, Didona D, Donati M, Donati P. Folliculotropic cutaneous metastases and lymphangitis carcinomatosa: when cutaneous metastases of breast carcinoma are mistaken for cutaneous infections. *Acta Dermatovenerol Croat*. 2016;24(2):154–7.
44. Martynychnen MG, Rabelo LM, Silva RL, Escuissato DL. Carcinomatous lymphangitis as the initial manifestation of ovarian adenocarcinoma. *J Bras Pneumol*. 2007;33(5):609–11 (English, Portuguese).
45. Prat L, Chouaid C, Kettaneh A, Fardet L. Cutaneous lymphangitis carcinomatosa in a patient with lung adenocarcinoma: case report and literature review. *Lung Cancer*. 2013;79(1):91–3.
46. Nakamura F, Seino M, Suzuki Y, Sakaki H, Sudo T, Ohta T, Tsutsumi S, Nagase S. Successful management of cutaneous lymphangitis carcinomatosa arising from cervical cancer with paclitaxel-cisplatin and bevacizumab combination therapy: a case report and review of the literature. *J Med Case Rep*. 2019;13(1):328.
47. Granata V, Fusco R, Bicchierai G, Cozzi D, Grazzini G, Danti G, De Muzio F, Maggioletti N, Smorchkova O, D'Elia M, Brunese MC, Grassi R, Giacobbe G, Bruno F, Palumbo P, Lacasella GV, Brunese L, Grassi R, Miele V, Barile A. Diagnostic protocols in oncology: workup and treatment planning. Part 1: the optimization of CT protocol. *Eur Rev Med Pharmacol Sci*. 2021;25(22):6972–94.
48. Granata V, Bicchierai G, Fusco R, Cozzi D, Grazzini G, Danti G, De Muzio F, Maggioletti N, Smorchkova O, D'Elia M, Brunese MC, Grassi R, Giacobbe G, Bruno F, Palumbo P, Grassi F, Brunese L, Grassi R, Miele V, Barile A. Diagnostic protocols in oncology: workup and treatment planning. Part 2: abbreviated MR protocol. *Eur Rev Med Pharmacol Sci*. 2021;25(21):6499–528.
49. Fusco R, Granata V, Sansone M, Rega D, Delrio P, Tatangelo F, Romano C, Avallone A, Pupo D, Giordano M, Grassi R, Ravo V, Pecori B, Petrillo A. Validation of the standardized index of shape tool to analyze DCE-MRI data in the assessment of neo-adjuvant therapy in locally advanced rectal cancer. *Radiol Med*. 2021;126:1044–54.
50. Rampado O, Depaoli A, Marchisio F, Gatti M, Racine D, Ruggeri V, Ruggeriello I, Darvizeh F, Fonio P, Ropolo R. Effects of different levels of CT iterative reconstruction on low-contrast detectability and radiation dose in patients of different sizes: an anthropomorphic phantom study. *Radiol Med*. 2021;126(1):55–62.
51. Schicchi N, Fogante M, Palumbo P, Agliata G, Esposto Pirani P, Di Cesare E, Giovagnoni A. The sub-millisievert era in CTCA: the technical basis of the new radiation dose approach. *Radiol Med*. 2020;125(11):1024–39.
52. Palumbo P, Cannizzaro E, Bruno F, Schicchi N, Fogante M, Agostini A, De Donato MC, De Cataldo C, Giovagnoni A, Barile A, Splendiani A, Masciocchi C, Di Cesare E. Coronary artery disease (CAD) extension-derived risk stratification for asymptomatic diabetic patients: usefulness of low-dose coronary computed tomography angiography (CCTA) in detecting high-risk profile patients. *Radiol Med*. 2020;125(12):1249–59.
53. Agostini A, Floridi C, Borgheresi A, Badaloni M, Esposto Pirani P, Terilli F, Ottaviani L, Giovagnoni A. Proposal of a low-dose, long-pitch, dual-source chest CT protocol on third-generation dual-source CT using a tin filter for spectral shaping at 100 kVp for Coronavirus Disease 2019 (COVID-19) patients: a feasibility study. *Radiol Med*. 2020;125(4):365–73.
54. Esposito A, Gallone G, Palmisano A, Marchitelli L, Catapano F, Francone M. The current landscape of imaging recommendations in cardiovascular clinical guidelines: toward an imaging-guided precision medicine. *Radiol Med*. 2020;125(11):1013–23.
55. Bastiani L, Paolicchi F, Faggioni L, Martinelli M, Gerasia R, Martini C, Cornacchione P, Ceccarelli M, Chiappino D, Della Latta D, Negri J, Pertoldi D, Negro D, Nuzzi G, Rizzo V, Tamburrino P, Pozzessere C, Aringhieri G, Caramella D. Patient perceptions and knowledge of ionizing radiation from medical imaging. *JAMA Netw Open*. 2021;4(10): e2128561. <https://doi.org/10.1001/jamanetworkopen.2021.28561> (Erratum.In:JAMANetw Open.2021Dec1;4(12):e2141299).
56. Lane DL, Neelapu SS, Xu G, Weaver O. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or prior breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT, and PET-CT. *Korean J Radiol*. 2021;22(12):1938–45.
57. Becker AS, Perez-Johnston R, Chikarmane SA, Chen MM, El Homsy M, Feigin KN, Gallagher KM, Hanna EY, Hicks M, Illica AT, Mayer EL, Shinagare AB, Yeh R, Mayerhoefer ME, Hricak H, Vargas HA. Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: radiology scientific expert panel. *Radiology*. 2021;300(2):E323–7.
58. Sansone M, Grassi R, Belfiore MP, Gatta G, Grassi F, Pinto F, La Casella GV, Fusco R, Cappabianca S, Granata V, Grassi R. Radiomic features of breast parenchyma: assessing differences between FOR PROCESSING and FOR PRESENTATION digital mammography. *Insights Imaging*. 2021;12(1):147.
59. Fusco R, Granata V, Mattace Raso M, Vallone P, De Rosa AP, Siani C, Di Bonito M, Petrillo A, Sansone M. Blood oxygenation level dependent magnetic resonance imaging (MRI), dynamic contrast enhanced MRI, and diffusion weighted MRI for benign and malignant breast cancer discrimination: a preliminary experience. *Cancers (Basel)*. 2021;13(10):2421.
60. Petrillo A, Fusco R, Vallone P, Filice S, Granata V, Petrosino T, Rosaria Rubulotta M, Setola SV, Mattace Raso M, Maio F, Raiano C, Siani C, Di Bonito M, Botti G. Digital breast tomosynthesis and contrast-enhanced dual-energy digital mammography alone and in combination compared to 2D digital synthesized mammography and MR imaging in breast cancer detection and classification. *Breast J*. 2020;26(5):860–72.
61. Fusco R, Sansone M, Granata V, Di Bonito M, Avino F, Catalano O, Botti G, Petrillo A. Use of quantitative morphological and functional features for assessment of axillary lymph node in breast dynamic contrast-enhanced magnetic resonance imaging. *Biomed Res Int*. 2018;30(2018):2610801.
62. Girometti R, Linda A, Conte P, Lorenzon M, De Serio I, Jerman K, Londero V, Zuiani C. Multireader comparison of contrast-enhanced mammography versus the combination of digital mammography and digital breast tomosynthesis in the preoperative assessment of breast cancer. *Radiol Med*. 2021;126(11):1407–14.
63. Bellardita L, Colciago RR, Frasca S, De Santis MC, Gay S, Palorini F, La Rocca E, Valdagni R, Rancati T, Lozza L. Breast cancer patient perspective on opportunities and challenges of a genetic test aimed to predict radio-induced side effects before treatment: analysis of the Italian branch of the REQUITE project. *Radiol Med*. 2021;126(10):1366–73.
64. Deandrea S, Cavazzana L, Principi N, Luconi E, Campoleoni M, Bastiampillai AJ, Bracchi L, Bucchi L, Pedilarco S, Piscitelli A, Sfondrini MS, Silvestri AR, Castaldi S. Screening of women with aesthetic prostheses in dedicated sessions of a population-based breast cancer screening programme. *Radiol Med*. 2021;126(7):946–55.
65. Nori J, Bicchierai G, Amato F, De Benedetto D, Boeri C, Vanzi E, Di Naro F, Bianchi S, Miele V. A new technique for the histological diagnosis of Paget's disease of the breast using a semiautomated core needle biopsy with a 14-gauge needle. *Radiol Med*. 2021;126(7):936–45.
66. Trombadori CML, D'Angelo A, Ferrara F, Santoro A, Belli P, Manfredi R. Radial scar: a management dilemma. *Radiol Med*. 2021;126(6):774–85.
67. Romanucci G, Mercogliano S, Carucci E, Cina A, Zantedeschi E, Caneva A, Benassuti C, Fornasa F. Diagnostic accuracy of resection margin in

specimen radiography: digital breast tomosynthesis versus full-field digital mammography. *Radiol Med.* 2021;126(6):768–73.

68. D'Angelo A, Orlandi A, Bufi E, Mercogliano S, Belli P, Manfredi R. Automated breast volume scanner (ABVS) compared to handheld ultrasound (HHUS) and contrast-enhanced magnetic resonance imaging (CE-MRI) in the early assessment of breast cancer during neoadjuvant chemotherapy: an emerging role to monitoring tumor response? *Radiol Med.* 2021;126(4):517–26.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

